Recruiting

Testing two medications before and after melanoma surgery

Plain-English translation of NCT06965231 on ClinicalTrials.gov ↗ · Source last updated May 2025 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a combination of two medications called toripalimab and endostatin (Endostar) for people with stage II melanoma of the skin. You would receive toripalimab before surgery to shrink the tumor, then have it surgically removed, and continue both medications afterward to reduce the chance of the cancer returning. The study will follow you for up to 2 years to see if this approach prevents recurrence and is safe.

Right now, many people with stage II melanoma experience cancer recurrence even after surgery. This trial is testing whether giving these two medications together—one that boosts the immune system and one that blocks blood vessel growth—can help keep the cancer from coming back and become a new standard treatment option.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with stage II cutaneous or actal melanoma (skin melanoma on hands or feet) confirmed by biopsy
you have never received cancer treatment before
your blood counts, liver function, kidney function, and heart function are within acceptable ranges
you are willing to use contraception during the study and for 6 months after completion

You likely don't qualify if…

you have had an allergic reaction to biological medications
you have had another cancer diagnosis in the past 5 years (except certain skin cancers)
you have an active autoimmune disease that requires ongoing treatment
you have a bleeding disorder or have had recent severe bleeding
you have uncontrolled high blood pressure, heart disease, or other serious medical conditions

What participation looks like

You would start by receiving two doses of toripalimab before your melanoma surgery. After surgery, you would receive toripalimab injections every 2 weeks and endostatin through an IV infusion (continuously over 72 hours) every 4 weeks for several months. Throughout the study and for up to 2 years after, you would have regular clinic visits for blood tests, imaging scans, and check-ups to monitor for side effects and watch for any signs of cancer recurrence.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Testing two medications before and after melanoma surgery

What is this trial?

Do you qualify?

What participation looks like

Trial locations